CervoMed Inc.
Close on Oct 19, 2026
- Market cap
- $23.66M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 18, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 17, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | $300.00K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | $1.80M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | $1.90M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | $1.90M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 15, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 5, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | After market close | – | – | – |
Press releases
Announcements CervoMed filed with the SEC
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
CervoMed Announces New Data at the AD/PD ™ 2026 Scientific Conference that Reinforce Neflamapimod ’ s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer ’ s Disease Co-Pathology
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed ’ s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod ’ s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Material agreement · Results of operations · EX-99.1 to Form 8-K
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD ™ 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8 th International Lewy Body Dementia Conference
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · Other events · EX-99.1 to Form 8-K
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
Results of operations · Other events · EX-99.2 to Form 8-K
CervoMed Announces Key Senior Leadership Appointments
Results of operations · Other events · EX-99.3 to Form 8-K
CervoMed Announces Key Takeaways from Oral Presentations at the 17 th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Other events · EX-99.1 to Form 8-K
CervoMed to Deliver Oral Presentation at the 8 th International Lewy Body Dementia Conference
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K